US 12,403,121 B2
Anticancer rocaglamide derivatives
Long-Sheng Chang, Hilliard, OH (US); and A. Douglas Kinghorn, Columbus, OH (US)
Assigned to The Research Institute at Nationwide Children's Hospital, Columbus, OH (US)
Appl. No. 17/284,112
Filed by The Research Institute at Nationwide Children's Hospital, Columbus, OH (US)
PCT Filed Oct. 9, 2019, PCT No. PCT/US2019/055304
§ 371(c)(1), (2) Date Apr. 9, 2021,
PCT Pub. No. WO2020/076889, PCT Pub. Date Apr. 16, 2020.
Claims priority of provisional application 62/743,230, filed on Oct. 9, 2018.
Prior Publication US 2021/0346337 A1, Nov. 11, 2021
Int. Cl. A61K 31/343 (2006.01); A61K 9/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/343 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61P 35/00 (2018.01)] 13 Claims
 
1. A method of treating cancer in a subject in need thereof, consisting of administering a therapeutically effective amount of a compound according to formula I to the subject:

OG Complex Work Unit Chemistry
wherein R1 is selected from the group consisting of —OH, —OAc, —OCHO, ═O, and ═NOH; R2 is selected from the group consisting of —CON(CH3)2, —CONHCH3, —CONH2, —COOCH3, —COOH, and —H, R3 is selected from the group consisting of —H, —OH, and —OCH3, and R4 is selected from the group consisting of —OH, —OCH3, —OCH2CH3, and optionally a pharmaceutically acceptable carrier,
wherein the cancer is selected from malignant peripheral nerve sheath tumors, Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.